Pretreatment serum levels of protein S100A9 in a UK cohort of 236 patients with RA did not correlate with EULAR response to etanercept, despite promising results from a previous small-scale study. Levels of S100A9 were not associated with moderate response (P = 0.957 versus non-response) or good response (P = 0.316 versus non-response) to etanercept. Pretreatment levels of S100A9 also did not correlate with any clinical parameters of disease activity (P > 0.05).
References
Smith, S. L. et al. The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology (Oxford) http://dx.doi.org/10.1093/rheumatology/kew387 (2017)
Rights and permissions
About this article
Cite this article
Collison, J. S100A9 does not predict response to etanercept. Nat Rev Rheumatol 13, 130 (2017). https://doi.org/10.1038/nrrheum.2017.13
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.13
